we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.
Company profile
Ticker
LYEL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
833006753
LYEL stock data
Latest filings (excl ownership)
S-3
Shelf registration
28 Feb 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
28 Feb 24
8-K
Departure of Directors or Certain Officers
20 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
7 Nov 23
8-K
Regulation FD Disclosure
11 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
8 Aug 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 286.50 mm | 286.50 mm | 286.50 mm | 286.50 mm | 286.50 mm | 286.50 mm |
Cash burn (monthly) | (no burn) | (no burn) | 19.68 mm | 16.86 mm | 12.56 mm | 13.61 mm |
Cash used (since last report) | n/a | n/a | 131.35 mm | 112.51 mm | 83.84 mm | 90.84 mm |
Cash remaining | n/a | n/a | 155.15 mm | 173.99 mm | 202.65 mm | 195.66 mm |
Runway (months of cash) | n/a | n/a | 7.9 | 10.3 | 16.1 | 14.4 |
Institutional ownership, Q3 2023
72.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 108 |
Opened positions | 16 |
Closed positions | 9 |
Increased positions | 47 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 179.11 bn |
Total shares | 183.96 mm |
Total puts | 2.20 k |
Total calls | 10.20 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
ARCH Venture Fund IX | 36.41 mm | $0.00 |
MWG Management | 20.16 mm | $29.64 bn |
Vanguard | 16.91 mm | $24.86 bn |
Orland Properties | 15.09 mm | $22.19 bn |
NEWTON (PTC) | 15.09 mm | $0.00 |
BLK Blackrock | 13.42 mm | $19.73 bn |
Foresite Capital Fund IV | 10.00 mm | $0.00 |
Foresite Capital Management IV | 8.78 mm | $12.91 bn |
STT State Street | 6.81 mm | $10.01 bn |
T. Rowe Price | 6.69 mm | $9.82 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Feb 24 | Lang Matthew | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 50,000 |
9 Feb 24 | Lang Matthew | Option Common Stock | Grant | Acquire A | No | No | 1.8 | 500,000 | 900.00 k | 500,000 |
9 Feb 24 | Stephen J. Hill | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 48,928 |
9 Feb 24 | Stephen J. Hill | Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 400,000 | 720.00 k | 400,000 |
9 Feb 24 | Gary K. Lee | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 52,700 |
9 Feb 24 | Gary K. Lee | Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 400,000 | 720.00 k | 400,000 |
9 Feb 24 | Charles W. Newton | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 48,729 |
9 Feb 24 | Charles W. Newton | Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 400,000 | 720.00 k | 400,000 |
9 Feb 24 | Seely Lynn | Common Stock | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 200,000 |
News
Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
16 Apr 24
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 Apr 24
Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday
12 Apr 24
12 Health Care Stocks Moving In Thursday's After-Market Session
11 Apr 24
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
9 Apr 24